{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:59:13Z","timestamp":1787032753682,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,27]]},"DOI":"10.7759\/cureus.13588","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T08:14:16Z","timestamp":1614413656000},"source":"Crossref","is-referenced-by-count":2,"title":["Crippling Side Effects Induced by Paliperidone Palmitate Treatment: A Case Report"],"prefix":"10.7759","author":[{"given":"Tamadhir","family":"Al-Mahrouqi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameera","family":"Al-Kindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Harrasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","article-title":"Diagnostic And Statistical Manual Of Mental Disorders, Fifth Edition","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic And Statistical Manual Of Mental Disorders, Fifth Edition. American Psychiatric Association Publishing, Washington, DC; 2013. 10.1176\/appi.books.9780890425596"},{"key":"ref2","article-title":"The Maudsley Prescribing Guidelines in Psychiatry, 13th Edition","author":"Taylor DM","year":"2020","unstructured":"Taylor DM, Barnes TR, Young AH. The Maudsley Prescribing Guidelines in Psychiatry, 13th Edition. Wiley-Blackwell, Hoboken, NJ; 2020."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1708\/3281.32542","article-title":"Paliperidone palmitate in short- and long-term treatment of schizophrenia","volume":"54","author":"Valsecchi P","year":"2019","unstructured":"Valsecchi P, Barlati S, Garozzo A, et al.. Paliperidone palmitate in short- and long-term treatment of schizophrenia. Riv Psichiatr. 2019, 54:235-48. 10.1708\/3281.32542","journal-title":"Riv Psichiatr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/00131746-200101000-00005","article-title":"Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications","volume":"7","author":"Weiden PJ","year":"2001","unstructured":"Weiden PJ, Miller AL. Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. J Psychiatr Pract. 2001, 7:41-7. 10.1097\/00131746-200101000-00005","journal-title":"J Psychiatr Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2019.014","article-title":"Drug-induced movement disorders","volume":"42","author":"Duma SR","year":"2019","unstructured":"Duma SR, Fung VS. Drug-induced movement disorders. Aust Prescr. 2019, 42:56-61. 10.18773\/austprescr.2019.014","journal-title":"Aust Prescr"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40501-018-0137-1","article-title":"Use of antipsychotic drugs for psychotic disorders in children","volume":"5","author":"Ayub S","year":"2018","unstructured":"Ayub S, Ramtekkar U, Reiersen AM. Use of antipsychotic drugs for psychotic disorders in children. Curr Treat Options Psychiatry. 2018, 5:1-5. 10.1007\/s40501-018-0137-1","journal-title":"Curr Treat Options Psychiatry"},{"key":"ref7","article-title":"Strategies for dosing and switching antipsychotics for optimal clinical management","volume":"69","author":"Buckley PF","year":"2008","unstructured":"Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry. 2008, 69:4-17.","journal-title":"J Clin Psychiatry"},{"key":"ref8","article-title":"Prescriber's Guide: Stahl's Essential Psychopharmacology","author":"Stahl SM","year":"2021","unstructured":"Stahl SM. Prescriber's Guide: Stahl's Essential Psychopharmacology. Cambridge University Press, Cambridge, UK; 2021."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.2010.22.4.451.e37","article-title":"Paliperidone-induced dystonic dysphagia","volume":"22","author":"Mendhekar DN","year":"2010","unstructured":"Mendhekar DN, Agarwal A. Paliperidone-induced dystonic dysphagia. J Neuropsychiatry Clin Neurosci. 2010, 22:451. 10.1176\/jnp.2010.22.4.451.e37","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2016.04.006","article-title":"A case of tardive dystonia associated with long-acting injectable paliperidone palmitate","volume":"26","author":"Ma CH","year":"2016","unstructured":"Ma CH, Chien YL, Liu CC, Chen IM, Lin CH. A case of tardive dystonia associated with long-acting injectable paliperidone palmitate. Eur Neuropsychopharmacol. 2016, 26:1251-2. 10.1016\/j.euroneuro.2016.04.006","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00455-006-9032-9","article-title":"Neuroleptic-induced dysphagia: case report and literature review","volume":"22","author":"Dziewas R","year":"2007","unstructured":"Dziewas R, Warnecke T, Schnabel M, et al.. Neuroleptic-induced dysphagia: case report and literature review. Dysphagia. 2007, 22:63-7. 10.1007\/s00455-006-9032-9","journal-title":"Dysphagia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32833db3d8","article-title":"Tolerability of paliperidone: a meta-analysis of randomized, controlled trials","volume":"25","author":"Harrington CA","year":"2010","unstructured":"Harrington CA, English C. Tolerability of paliperidone: a meta-analysis of randomized, controlled trials. Int Clin Psychopharmacol. 2010, 25:334-41. 10.1097\/YIC.0b013e32833db3d8","journal-title":"Int Clin Psychopharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2005.41.6.893628","article-title":"Drug-induced sialorrhea","volume":"41","author":"Freudenreich O","year":"2005","unstructured":"Freudenreich O. Drug-induced sialorrhea. Drugs Today (Barc). 2005, 41:411-8. 10.1358\/dot.2005.41.6.893628","journal-title":"Drugs Today (Barc)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.17826\/cutf.254574","article-title":"Paliperidone palmitate-induced sialorrhoea","volume":"41","author":"Cengisiz C","year":"2016","unstructured":"Cengisiz C, Tu\u011fal \u00d6, \u00d6zenli Y. Paliperidone palmitate-induced sialorrhoea. Cukurova Med J. 2016, 41:8-13. 10.17826\/cutf.254574","journal-title":"Cukurova Med J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-221771","article-title":"Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability","volume":"2018","author":"Tagne Nouemssi AB","year":"2018","unstructured":"Tagne Nouemssi AB. Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability. BMJ Case Rep. 2018, 2018:bcr2017221771. 10.1136\/bcr-2017-221771","journal-title":"BMJ Case Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2016.14.1.96","article-title":"Paliperidone palmitate-induced urinary incontinence: a case report","volume":"14","author":"Karsl\u0131o\u01e7lu EH","year":"2016","unstructured":"Karsl\u0131o\u01e7lu EH, \u00d6zalp E, \u00c7ayk\u00f6yl\u00fc A. Paliperidone palmitate-induced urinary incontinence: a case report. Clin Psychopharmacol Neurosci. 2016, 14:96-100. 10.9758\/cpn.2016.14.1.96","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2016.07.185","article-title":"Management of antipsychotic-induced hyperprolactinemia","volume":"6","author":"Tewksbury A","year":"2016","unstructured":"Tewksbury A, Olander A. Management of antipsychotic-induced hyperprolactinemia. Ment Health Clin. 2016, 6:185-90. 10.9740\/mhc.2016.07.185","journal-title":"Ment Health Clin"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s0306-4530(02)00127-0","article-title":"Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone","volume":"28","author":"Kinon BJ","year":"2003","unstructured":"Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003, 28:55-68. 10.1016\/s0306-4530(02)00127-0","journal-title":"Psychoneuroendocrinology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s0024-3205(02)01775-7","article-title":"Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia","volume":"71","author":"Meaney AM","year":"2002","unstructured":"Meaney AM, O'Keane V. Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia. Life Sci. 2002, 71:979-92. 10.1016\/s0024-3205(02)01775-7","journal-title":"Life Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/48984-crippling-side-effects-induced-by-paliperidone-palmitate-treatment-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T14:26:44Z","timestamp":1707488804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/48984-crippling-side-effects-induced-by-paliperidone-palmitate-treatment-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,27]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.13588","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,27]]}}}